281 related articles for article (PubMed ID: 30982303)
61. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
62. Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore.
Chua CG; Low JZ; Lim WY; Manghani M
Ann Acad Med Singap; 2022 Dec; 51(12):755-765. PubMed ID: 36592144
[TBL] [Abstract][Full Text] [Related]
63. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
[TBL] [Abstract][Full Text] [Related]
64. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis.
Trallero-Araguás E; Rodrigo-Pendás JÁ; Selva-O'Callaghan A; Martínez-Gómez X; Bosch X; Labrador-Horrillo M; Grau-Junyent JM; Vilardell-Tarrés M
Arthritis Rheum; 2012 Feb; 64(2):523-32. PubMed ID: 21953614
[TBL] [Abstract][Full Text] [Related]
65. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
66. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
[TBL] [Abstract][Full Text] [Related]
67. Cancer risk in dermatomyositis: a systematic review of the literature.
Di Rollo D; Abeni D; Tracanna M; Capo A; Amerio P
G Ital Dermatol Venereol; 2014 Oct; 149(5):525-37. PubMed ID: 24975953
[TBL] [Abstract][Full Text] [Related]
68. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
69. [Dermatomyositis: a paraneoplastic symptom].
Benito Alonso E; Hidalgo Vera P; Ontañón Nasarre B; Bronchalo González C
Semergen; 2012; 38(1):60-3. PubMed ID: 24847543
[TBL] [Abstract][Full Text] [Related]
70. [Classic/amyopathic dermatomyositis].
Vilas AP; Fiúza T
Acta Med Port; 2000; 13(5-6):287-94. PubMed ID: 11234494
[TBL] [Abstract][Full Text] [Related]
71. Paraneoplastic Wong-Type Dermatomyositis Associated with Gynecological Malignancy.
Russo R; Gasparini G; Cozzani E; Gravina B; Parodi A
Medicina (Kaunas); 2022 Mar; 58(4):. PubMed ID: 35454323
[TBL] [Abstract][Full Text] [Related]
72. Dermatomyositis-erythrodermia: clinical presentation not associated to malignancy. A case report.
Valdés-González G; Chávez-López M; Gallaga-Gutiérrez A; Reyes-García A
Reumatol Clin; 2014; 10(1):48-50. PubMed ID: 23545145
[TBL] [Abstract][Full Text] [Related]
73. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
[TBL] [Abstract][Full Text] [Related]
74. A rare case of severe myositis as paraneoplastic syndrome on breast cancer.
Dias LP; Faria AL; Scandiuzzi MM; Inhaia CL; Shida JY; Gebrim LH
World J Surg Oncol; 2015 Apr; 13():134. PubMed ID: 25890160
[TBL] [Abstract][Full Text] [Related]
75. Dermatomyositis paraneoplastic syndrome before symptomatic tonsillar squamous cell carcinoma: a case report.
Adi AH; Alturkmani H; Spock T; Williams Yohannes P; Wargo S; Szabo E; Gutkind JS; Van Waes C
Head Neck; 2015 Jan; 37(1):E1-3. PubMed ID: 24715579
[TBL] [Abstract][Full Text] [Related]
76. Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis.
Satoh M; Chan JY; Ross SJ; Li Y; Yamasaki Y; Yamada H; Vazquez-del Mercado M; Petri MH; Jara LJ; Saavedra MA; Cruz-Reyes C; Sobel ES; Reeves WH; Ceribelli A; Chan EK
Arthritis Res Ther; 2012 Apr; 14(2):R79. PubMed ID: 22513056
[TBL] [Abstract][Full Text] [Related]
77. Paraneoplastic dermatomyositis accompanying nasopharyngeal carcinoma: diagnosis, treatment and prognosis.
Chakroun A; Guigay J; Lusinchi A; Marandas P; Janot F; Hartl DM
Eur Ann Otorhinolaryngol Head Neck Dis; 2011 Jun; 128(3):127-31. PubMed ID: 21257359
[TBL] [Abstract][Full Text] [Related]
78. Anti-Hu paraneoplastic brainstem encephalitis caused by a pancreatic neuroendocrine tumor presenting with central hypoventilation.
Najjar M; Taylor A; Agrawal S; Fojo T; Merkler AE; Rosenblum MK; Lennihan L; Kluger MD
J Clin Neurosci; 2017 Jun; 40():72-73. PubMed ID: 28256369
[TBL] [Abstract][Full Text] [Related]
79. Dermatomyositis as the first manifestation of a lung tumor.
Castro AS; Barroso A; Parente B
Rev Port Pneumol; 2013; 19(4):179-83. PubMed ID: 23602006
[TBL] [Abstract][Full Text] [Related]
80. Case report of anti-transcription intermediary factor-1-γ/α antibody-positive dermatomyositis associated with gastric cancer and immunoglobulin G4-positive pulmonary inflammatory pseudotumor.
Ito K; Imafuku S; Hamaguchi Y; Fujimoto M; Nakayama J
J Dermatol; 2013 Jul; 40(7):567-9. PubMed ID: 23663102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
